A novel human ventricular cardiac anisotropic sheet (hvCAS) using pluripotent stem-cell-derived cardiomyocytes allows direct visualization of arrhythmic spiral re-entry to assess drug arrhythmogenicity.
The hvCAS biohybrid material represents a novel preclinical tool for directly visualizing and assessing drug-induced arrhythmogenicity.
A novel cardiomimetic biohybrid material, termed as the human ventricular cardiac anisotropic sheet (hvCAS) is reported. Well-characterized human pluripotent stem-cell-derived ventricular cardiomyocytes are strategically aligned to reproduce key electrophysiological features of native human ventricle, which, along with specific selection criteria, allows for a direct visualization of arrhythmic spiral re-entry and represents a revolutionary tool to assess preclinical drug-induced arrhythmogenicity. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Shum et al. (Wed,) conducted a other in Preclinical drug-induced arrhythmogenicity. Human ventricular cardiac anisotropic sheet (hvCAS) was evaluated on Visualization of arrhythmic spiral re-entry. A novel human ventricular cardiac anisotropic sheet (hvCAS) using pluripotent stem-cell-derived cardiomyocytes allows direct visualization of arrhythmic spiral re-entry to assess drug arrhythmogenicity.